U.S. court reverses ban on sales of Sanofi, Regeneron drug Praluent

(Reuters) - A U.S. appeals court has thrown out a ban on sales of Sanofi SA and Regeneron Pharmaceuticals Inc's cholesterol-lowering drug Praluent, in a closely watched case that could have broad implications for drug development.